Showing results (1721-1730 of 2,107) with videos related to
Sort By:
Pageof 211
CNS Drugs|December 6, 2017
Comparing Safety and Efficacy of "Third-Generation" Antiepileptic Drugs: Long-Term Extension and Post-marketing TreatmentCharlotte S Kwok, Emily L Johnson, Gregory L KraussCNS Drugs|February 4, 2019
Mixed States: Modelling and ManagementGin S Malhi, Kristina Fritz, Preeya Elangovan, et al.CNS Drugs|March 18, 2018
Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled TrialJayashri Kulkarni, Natalie Thomas, Abdul-Rahman Hudaib, et al.CNS Drugs|July 6, 2016
A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE StudyPeter J Weiden, Raymond Manning, Curt D Wolfgang, et al.CNS Drugs|June 18, 2016
A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' DatabaseStefania Chiappini, Fabrizio SchifanoCNS Drugs|January 5, 2002
Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol)Karim Makhlouf, Howard L Weiner, Samia J KhouryCNS Drugs|January 5, 2002
Effects of newer antipsychotics on extrapyramidal functionDaniel Tarsy, Ross J Baldessarini, Frank I TaraziCNS Drugs|January 5, 2002
Efficacy and safety of tianeptine in major depression: evidence from a 3-month controlled clinical trial versus paroxetineLionel Waintraub, Lucia Septien, Paul AzoulayCNS Drugs|November 9, 2001
Olanzapine: a review of its use in the treatment of bipolar I disorderN Bhana, C M PerryCNS Drugs|February 5, 2002
Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence?David C HendersonPageof 211